Immunovant Inc (IMVT)

Immunovant Inc (IMVT) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.9B; returns 1 day -2.4%, 1 week +6.3%, 1 year +51.6%.

Immunovant Inc. (IMVT) is a clinical-stage biopharmaceutical company dedicated to developing novel antibody therapies for serious autoantibody-driven diseases. The company's business model is centered on the research, development, and eventual commercialization of its product candidates, as it currently generates no revenue from product sales.

Groups IMVT belongs to

• Biotechnology
• Biopharmaceutical
• Clinical Stage Biotech
• Clinical Stage Biopharma
• Autoimmune Diseases
• Antibody Therapeutics
• Healthcare
• Monoclonal Antibodies
• Life Sciences
• Rare Diseases
• Chronic Disease Management
• Rheumatoid Arthritis

IMVT financial model: income statement, cash flow and balance sheet